首页 > 最新文献

Neuro-oncology practice最新文献

英文 中文
Trends in the incidence of malignant central nervous system tumors in Brazil, 2000-2015. 2000-2015年巴西恶性中枢神经系统肿瘤发病率趋势
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.1093/nop/npac063
Letícia Lima de Oliveira, Anke Bergmann, Luiz Claudio Santos Thuler

Background: In Brazil, 5870 new cases of malignant central nervous system tumors (MCNST) were estimated for men and 5220 for women for each year of the 2020-2022 triennium. The objective of this study was to analyze incidence rate trends and compare demographic characteristics of new MCNST cases according to tumor topographies in Brazil from 2000 to 2015.

Methods: This study comprises an analytical cross-sectional assessment of secondary databases extracted from the Brazilian National Cancer Institute (INCA) website. Data comprised new neoplasm cases of meninges (C70), brain (C71), spinal cord, cranial nerves, and other central nervous system parts (C72) retrieved from 23 population-based cancer registries. A descriptive analysis was performed. Crude and age-adjusted incidence rates were calculated. Linear trends were calculated using a linear least squares regression for adjusted incidence rates versus time.

Results: A total of 24 986 new MCNST cases were recorded. The main topography was the brain (91.5%). Except for meninges tumors, where 62.4% of the cases were observed in women, MCNST cases were more frequent among men concerning the other evaluated topographies. All 3 topographies occurred predominantly in adult patients aged from 40- to 64-year-old. Between 2000 and 2015, incidence rates ranged from 5.12 to 4.95 (a 1.4% increase of per year; 95% CI -4.0 to 6.8; P = .584) in men and from 4.35 to 3.61 (a 3.1% increase per year; 95% CI -1.7 to 8.0; P = .189).

Conclusions: The most frequent topography was the brain. Incidence rates of MCNST remained relatively stable over time in both sexes.

背景:在巴西,估计在2020-2022年的三年期间,每年男性新发恶性中枢神经系统肿瘤(MCNST)为5870例,女性为5220例。本研究的目的是根据巴西2000年至2015年的肿瘤地形,分析发病率趋势并比较新发MCNST病例的人口统计学特征。方法:本研究包括从巴西国家癌症研究所(INCA)网站上提取的二级数据库的分析性横断面评估。数据包括从23个基于人群的癌症登记处检索的脑膜(C70)、脑(C71)、脊髓、脑神经和其他中枢神经系统部位(C72)的新发肿瘤病例。进行描述性分析。计算粗发病率和年龄调整后的发病率。使用线性最小二乘回归计算调整后发病率随时间的线性趋势。结果:共记录新发MCNST病例24 986例。主要地形为脑(91.5%)。除了脑膜肿瘤(女性占62.4%)外,在其他评估的地形中,MCNST病例在男性中更为常见。所有三种地形主要发生在40至64岁的成人患者中。2000年至2015年期间,发病率在5.12至4.95之间(每年增长1.4%;95% CI -4.0 ~ 6.8;P = .584),从4.35增加到3.61(每年增加3.1%;95% CI -1.7 ~ 8.0;P = .189)。结论:最常见的地形是脑部。随着时间的推移,MCNST的发病率在两性中保持相对稳定。
{"title":"Trends in the incidence of malignant central nervous system tumors in Brazil, 2000-2015.","authors":"Letícia Lima de Oliveira,&nbsp;Anke Bergmann,&nbsp;Luiz Claudio Santos Thuler","doi":"10.1093/nop/npac063","DOIUrl":"https://doi.org/10.1093/nop/npac063","url":null,"abstract":"<p><strong>Background: </strong>In Brazil, 5870 new cases of malignant central nervous system tumors (MCNST) were estimated for men and 5220 for women for each year of the 2020-2022 triennium. The objective of this study was to analyze incidence rate trends and compare demographic characteristics of new MCNST cases according to tumor topographies in Brazil from 2000 to 2015.</p><p><strong>Methods: </strong>This study comprises an analytical cross-sectional assessment of secondary databases extracted from the Brazilian National Cancer Institute (INCA) website. Data comprised new neoplasm cases of meninges (C70), brain (C71), spinal cord, cranial nerves, and other central nervous system parts (C72) retrieved from 23 population-based cancer registries. A descriptive analysis was performed. Crude and age-adjusted incidence rates were calculated. Linear trends were calculated using a linear least squares regression for adjusted incidence rates versus time.</p><p><strong>Results: </strong>A total of 24 986 new MCNST cases were recorded. The main topography was the brain (91.5%). Except for meninges tumors, where 62.4% of the cases were observed in women, MCNST cases were more frequent among men concerning the other evaluated topographies. All 3 topographies occurred predominantly in adult patients aged from 40- to 64-year-old. Between 2000 and 2015, incidence rates ranged from 5.12 to 4.95 (a 1.4% increase of per year; 95% CI -4.0 to 6.8; <i>P</i> = .584) in men and from 4.35 to 3.61 (a 3.1% increase per year; 95% CI -1.7 to 8.0; <i>P</i> = .189).</p><p><strong>Conclusions: </strong>The most frequent topography was the brain. Incidence rates of MCNST remained relatively stable over time in both sexes.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"34-40"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837770/pdf/npac063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10021447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma. 新诊断的胶质母细胞瘤患者的神经认知障碍、神经行为症状、疲劳、睡眠障碍和抑郁症状
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.1093/nop/npac068
Angela Sekely, Lori J Bernstein, Kristin L Campbell, Warren P Mason, Normand Laperriere, Navya Kalidindi, Rosemarylin Or, Ronald Ramos, Seth A Climans, Gregory R Pond, Barbara Ann Millar, David Shultz, Derek S Tsang, Gelareh Zadeh, Kim Edelstein

Background: In addition to poor survival rates, individuals with glioblastoma (GBM) are at risk of neurocognitive impairment due to multiple factors. This study aimed to characterize neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in newly diagnosed GBM patients; and to examine whether neurobehavioral symptoms, fatigue, sleep, and depressive symptoms influence neurocognitive performance.

Methods: This study was part of a prospective, inception cohort, single-arm exercise intervention in which GBM patients underwent a neuropsychological assessment shortly after diagnosis (median 4 weeks; ie, baseline) and 3, 6, 12, and 18 months later, or until tumor progression. Here, we present baseline data. Forty-five GBM patients (mean age = 55 years) completed objective neurocognitive tests, and self-report measures of neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms.

Results: Compared to normative samples, GBM patients scored significantly lower on all neurocognitive tests, with 34 (76%) patients exhibiting neurocognitive impairment. Specifically, 53% exhibited impairment in memory retention, 51% in executive function, 42% in immediate recall, 41% in verbal fluency, and 24% in attention. There were high rates of clinically elevated sleep disturbance (70%), fatigue (57%), depressive symptoms (16%), and neurobehavioral symptoms (27%). A multivariate regression analysis revealed that depressive symptoms are significantly associated with neurocognitive impairment.

Conclusions: GBM patients are vulnerable to adverse outcomes including neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis, prior to completing chemoradiation. Those with increased depressive symptoms are more likely to demonstrate neurocognitive impairment, highlighting the need for early identification and treatment of depression in this population.

背景:除了生存率低外,胶质母细胞瘤(GBM)患者由于多种因素还存在神经认知障碍的风险。本研究旨在描述新诊断的GBM患者的神经认知障碍、神经行为症状、疲劳、睡眠障碍和抑郁症状;并检查神经行为症状、疲劳、睡眠和抑郁症状是否会影响神经认知表现。方法:本研究是前瞻性、初始队列、单臂运动干预的一部分,GBM患者在诊断后不久接受神经心理学评估(中位4周;(基线)和3、6、12、18个月后,或直到肿瘤进展。这里,我们提供基线数据。45名GBM患者(平均年龄55岁)完成了客观的神经认知测试,并自我报告了神经行为症状、疲劳、睡眠障碍和抑郁症状。结果:与标准样本相比,GBM患者在所有神经认知测试中的得分明显较低,34例(76%)患者表现出神经认知障碍。具体来说,53%的人表现出记忆保持障碍,51%的人表现出执行功能障碍,42%的人表现出即时回忆障碍,41%的人表现出语言流畅性障碍,24%的人表现出注意力障碍。临床睡眠障碍(70%)、疲劳(57%)、抑郁症状(16%)和神经行为症状(27%)发生率较高。多元回归分析显示抑郁症状与神经认知功能障碍显著相关。结论:GBM患者在诊断后不久完成放化疗前易出现神经认知障碍、神经行为症状、疲劳、睡眠障碍和抑郁症状等不良结局。那些抑郁症状加重的人更有可能表现出神经认知障碍,这突出了在这一人群中早期识别和治疗抑郁症的必要性。
{"title":"Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.","authors":"Angela Sekely,&nbsp;Lori J Bernstein,&nbsp;Kristin L Campbell,&nbsp;Warren P Mason,&nbsp;Normand Laperriere,&nbsp;Navya Kalidindi,&nbsp;Rosemarylin Or,&nbsp;Ronald Ramos,&nbsp;Seth A Climans,&nbsp;Gregory R Pond,&nbsp;Barbara Ann Millar,&nbsp;David Shultz,&nbsp;Derek S Tsang,&nbsp;Gelareh Zadeh,&nbsp;Kim Edelstein","doi":"10.1093/nop/npac068","DOIUrl":"https://doi.org/10.1093/nop/npac068","url":null,"abstract":"<p><strong>Background: </strong>In addition to poor survival rates, individuals with glioblastoma (GBM) are at risk of neurocognitive impairment due to multiple factors. This study aimed to characterize neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in newly diagnosed GBM patients; and to examine whether neurobehavioral symptoms, fatigue, sleep, and depressive symptoms influence neurocognitive performance.</p><p><strong>Methods: </strong>This study was part of a prospective, inception cohort, single-arm exercise intervention in which GBM patients underwent a neuropsychological assessment shortly after diagnosis (median 4 weeks; ie, baseline) and 3, 6, 12, and 18 months later, or until tumor progression. Here, we present baseline data. Forty-five GBM patients (mean age = 55 years) completed objective neurocognitive tests, and self-report measures of neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms.</p><p><strong>Results: </strong>Compared to normative samples, GBM patients scored significantly lower on all neurocognitive tests, with 34 (76%) patients exhibiting neurocognitive impairment. Specifically, 53% exhibited impairment in memory retention, 51% in executive function, 42% in immediate recall, 41% in verbal fluency, and 24% in attention. There were high rates of clinically elevated sleep disturbance (70%), fatigue (57%), depressive symptoms (16%), and neurobehavioral symptoms (27%). A multivariate regression analysis revealed that depressive symptoms are significantly associated with neurocognitive impairment.</p><p><strong>Conclusions: </strong>GBM patients are vulnerable to adverse outcomes including neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis, prior to completing chemoradiation. Those with increased depressive symptoms are more likely to demonstrate neurocognitive impairment, highlighting the need for early identification and treatment of depression in this population.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"89-96"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837779/pdf/npac068.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10280730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of the utilization of telemedicine for brain tumor neurosurgery follow-up. 远程医疗在脑肿瘤神经外科随访中的应用安全性。
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.1093/nop/npac060
Alexis A Morell, Nitesh V Patel, Tiffany A Eatz, Adam S Levy, Daniel G Eichberg, Ashish H Shah, Evan Luther, Victor M Lu, Michael Kader, Dominique M O Higgins, Michael E Ivan, Ricardo J Komotar

Background: There is a need to evaluate the outcomes of patients who underwent brain tumor surgery with subsequent telemedicine or in-person follow-up during the COVID-19 pandemic.

Methods: We retrospectively included all patients who underwent surgery for brain tumor resection by a single neurosurgeon at our Institution from the beginning of the COVID-19 pandemic restrictions (March 2020) to August 2021. Outcomes were assessed by stratifying the patients using their preference for follow-up method (telemedicine or in-person).

Results: Three-hundred and eighteen (318) brain tumor patients who were included. The follow-up method of choice was telemedicine (TM) in 185 patients (58.17%), and in-person (IP) consults in 133 patients. We found that patients followed by TM lived significantly farther, with a median of 36.34 miles, compared to a median of 22.23 miles in the IP cohort (P = .0025). We found no statistical difference between the TM and the IP group, when comparing visits to the emergency department (ED) within 30 days after surgery (7.3% vs 6.01%, P = .72). Readmission rates, wound infections, and 30-day mortality were similar in both cohorts. These findings were also consistent after matching cohorts using a propensity score. The percentage of telemedicine follow-up consults was higher in the first semester (73.17%) of the COVID-19 pandemic, compared to the second (46.21%), and third semesters (47.86%).

Conclusions: Telehealth follow-up alternatives may be safely offered to patients after brain tumor surgery, thereby reducing patient burden in those with longer distances to the hospital or special situations as the COVID-19 pandemic.

背景:有必要评估在COVID-19大流行期间接受脑肿瘤手术的患者随后进行远程医疗或现场随访的结果。方法:我们回顾性纳入了从COVID-19大流行限制开始(2020年3月)到2021年8月在我们机构由一名神经外科医生进行脑肿瘤切除术的所有患者。通过患者偏好的随访方法(远程医疗或面对面)对结果进行分层评估。结果:共纳入318例脑肿瘤患者。随访方式选择远程医疗(TM) 185例(58.17%),当面咨询(IP) 133例。我们发现,与IP队列的中位数22.23英里相比,TM患者的中位数寿命明显更长,为36.34英里(P = 0.0025)。在比较手术后30天内急诊科(ED)就诊情况时,我们发现TM组与IP组之间无统计学差异(7.3% vs 6.01%, P = 0.72)。两组患者的再入院率、伤口感染和30天死亡率相似。在使用倾向评分匹配队列后,这些发现也是一致的。新冠肺炎大流行的第一学期(73.17%)远程医疗随访问诊比例高于第二学期(46.21%)和第三学期(47.86%)。结论:脑肿瘤手术后可安全提供远程医疗随访替代方案,从而减轻距离医院较远或COVID-19大流行等特殊情况下患者的负担。
{"title":"Safety of the utilization of telemedicine for brain tumor neurosurgery follow-up.","authors":"Alexis A Morell,&nbsp;Nitesh V Patel,&nbsp;Tiffany A Eatz,&nbsp;Adam S Levy,&nbsp;Daniel G Eichberg,&nbsp;Ashish H Shah,&nbsp;Evan Luther,&nbsp;Victor M Lu,&nbsp;Michael Kader,&nbsp;Dominique M O Higgins,&nbsp;Michael E Ivan,&nbsp;Ricardo J Komotar","doi":"10.1093/nop/npac060","DOIUrl":"https://doi.org/10.1093/nop/npac060","url":null,"abstract":"<p><strong>Background: </strong>There is a need to evaluate the outcomes of patients who underwent brain tumor surgery with subsequent telemedicine or in-person follow-up during the COVID-19 pandemic.</p><p><strong>Methods: </strong>We retrospectively included all patients who underwent surgery for brain tumor resection by a single neurosurgeon at our Institution from the beginning of the COVID-19 pandemic restrictions (March 2020) to August 2021. Outcomes were assessed by stratifying the patients using their preference for follow-up method (telemedicine or in-person).</p><p><strong>Results: </strong>Three-hundred and eighteen (318) brain tumor patients who were included. The follow-up method of choice was telemedicine (TM) in 185 patients (58.17%), and in-person (IP) consults in 133 patients. We found that patients followed by TM lived significantly farther, with a median of 36.34 miles, compared to a median of 22.23 miles in the IP cohort (<i>P</i> = .0025). We found no statistical difference between the TM and the IP group, when comparing visits to the emergency department (ED) within 30 days after surgery (7.3% vs 6.01%, <i>P</i> = .72). Readmission rates, wound infections, and 30-day mortality were similar in both cohorts. These findings were also consistent after matching cohorts using a propensity score. The percentage of telemedicine follow-up consults was higher in the first semester (73.17%) of the COVID-19 pandemic, compared to the second (46.21%), and third semesters (47.86%).</p><p><strong>Conclusions: </strong>Telehealth follow-up alternatives may be safely offered to patients after brain tumor surgery, thereby reducing patient burden in those with longer distances to the hospital or special situations as the COVID-19 pandemic.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"97-103"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10555120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reviewer List for the year 2022. 2022年审稿人名单。
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-02-01 DOI: 10.1093/nop/npad001
{"title":"Reviewer List for the year 2022.","authors":"","doi":"10.1093/nop/npad001","DOIUrl":"https://doi.org/10.1093/nop/npad001","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"107"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10556726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT). 非典型畸胎横纹肌瘤(ATRT)免疫疗法的最新进展。
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-01-28 eCollection Date: 2023-08-01 DOI: 10.1093/nop/npad005
Son Tran, Ashley S Plant-Fox, Susan N Chi, Aru Narendran

Atypical teratoid rhabdoid tumors (ATRT) are rare and aggressive embryonal tumors of central nervous system that typically affect children younger than 3 years of age. Given the generally poor outcomes of patients with ATRT and the significant toxicities associated with conventional multi-modal therapies, there is an urgent need for more novel approaches to treat ATRT, one such approach being immunotherapy. The recent rise of large-scale, multicenter interdisciplinary studies has delineated several molecular and genetic characteristics unique to ATRT. This review aims to describe currently available data on the tumor immune microenvironment of ATRT and its specific subtypes and to summarize the emerging clinical and preclinical results of immunotherapy-based approaches. It will also highlight the evolving knowledge of epigenetics on immunomodulation in this epigenetically influenced tumor, which may help guide the development of effective immunotherapeutic approaches in the future.

非典型畸形横纹肌瘤(ATRT)是一种罕见的侵袭性中枢神经系统胚胎性肿瘤,通常影响3岁以下的儿童。鉴于ATRT患者的预后普遍较差,而传统的多模式疗法又有明显的毒性,因此迫切需要更多新方法来治疗ATRT,免疫疗法就是其中之一。最近兴起的大规模、多中心、跨学科研究已经确定了 ATRT 独有的几个分子和遗传特征。本综述旨在描述 ATRT 及其特定亚型的肿瘤免疫微环境的现有数据,并总结基于免疫疗法的新临床和临床前研究结果。它还将强调表观遗传学对这种受表观遗传学影响的肿瘤的免疫调节的不断发展的认识,这可能有助于指导未来有效免疫治疗方法的开发。
{"title":"Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT).","authors":"Son Tran, Ashley S Plant-Fox, Susan N Chi, Aru Narendran","doi":"10.1093/nop/npad005","DOIUrl":"10.1093/nop/npad005","url":null,"abstract":"<p><p>Atypical teratoid rhabdoid tumors (ATRT) are rare and aggressive embryonal tumors of central nervous system that typically affect children younger than 3 years of age. Given the generally poor outcomes of patients with ATRT and the significant toxicities associated with conventional multi-modal therapies, there is an urgent need for more novel approaches to treat ATRT, one such approach being immunotherapy. The recent rise of large-scale, multicenter interdisciplinary studies has delineated several molecular and genetic characteristics unique to ATRT. This review aims to describe currently available data on the tumor immune microenvironment of ATRT and its specific subtypes and to summarize the emerging clinical and preclinical results of immunotherapy-based approaches. It will also highlight the evolving knowledge of epigenetics on immunomodulation in this epigenetically influenced tumor, which may help guide the development of effective immunotherapeutic approaches in the future.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 4","pages":"322-334"},"PeriodicalIF":2.7,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9881000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling. 通过DNA甲基化分析确定多形性黄细胞瘤成人患者手术切除和放疗后的临床疗效。
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-01-18 eCollection Date: 2023-06-01 DOI: 10.1093/nop/npad004
Maximilian Deng, Felix Hinz, Semi Harrabi, Dominik Sturm, Martin Sill, Andrey Korshunov, Tanja Eichkorn, Juliane Hörner-Rieber, Klaus Herfarth, Christine Jungk, Andreas Unterberg, Stefan Pfister, Wolfgang Wick, Andreas von Deimling, David Jones, Jürgen Debus, Felix Sahm, Laila König

Background: Molecular brain tumor classification using DNA methylation profiling has revealed that the methylation-class of pleomorphic xanthoastrocytoma (mcPXA) comprised a substantial portion of divergent initial diagnoses, which had been established based on histology alone. This study aimed to characterize the survival outcome in patients with mcPXAs-in light of the diverse selected treatment regimes.

Methods: A retrospective cohort of adult mcPXAs were analyzed in regard to their progression-free survival following surgical resection and postoperative radiotherapy. Radiotherapy treatment plans were correlated with follow-up images to characterize the pattern of relapse. Treatment toxicities and molecular tumor characteristics were further analyzed.

Results: Divergent initial histological diagnoses were encountered in 40.7%. There was no significant difference in local progression-free (PFS) and overall survival (OS) following gross total or subtotal resection. Postoperative radiotherapy was completed in 81% (22/27) following surgical intervention. Local PFS was 54.4% (95% CI: 35.3-84.0%) and OS was 81.3% (95% CI: 63.8-100%) after 3 years following postoperative radiotherapy. Initial relapses post-radiotherapy were primarily located in the previous tumor location and/or the planning target volume (PTV) (12/13). All patients in our cohort demonstrated the prognostically favorable pTERT-wildtype mcPXA.

Conclusion: Our study demonstrated that adult patients with mcPXAs display a worse progression-free survival compared to the reported WHO grade 2 PXAs. Future matched-pair analyses are required with a non-irradiated cohort to elucidate the benefit of postoperative radiotherapy in adult patients with mcPXAs.

背景:利用DNA甲基化图谱对脑肿瘤进行分子分类发现,甲基化类多形黄细胞瘤(mcPXA)占最初诊断分歧的很大一部分,而最初的诊断仅基于组织学。本研究旨在根据所选治疗方案的多样性,描述mcPXA患者的生存结果:方法:研究人员对一组成年 mcPXAs 患者进行了回顾性分析,了解他们在手术切除和术后放疗后的无进展生存期。将放疗治疗方案与随访图像进行关联,以确定复发模式的特征。对治疗毒性和肿瘤分子特征进行了进一步分析:结果:40.7%的患者最初的组织学诊断不一致。全切或次全切后的局部无进展生存期(PFS)和总生存期(OS)无明显差异。手术干预后,81%(22/27)的患者完成了术后放疗。术后放疗3年后,局部无进展生存期为54.4%(95% CI:35.3-84.0%),OS为81.3%(95% CI:63.8-100%)。放疗后的初次复发主要位于先前的肿瘤位置和/或规划靶区(PTV)(12/13)。我们队列中的所有患者均表现为预后良好的pTERT-野生型mcPXA:我们的研究表明,与已报道的WHO 2级PXA相比,成年mcPXA患者的无进展生存期更短。未来需要对非放疗队列进行配对分析,以阐明术后放疗对成年 mcPXA 患者的益处。
{"title":"Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling.","authors":"Maximilian Deng, Felix Hinz, Semi Harrabi, Dominik Sturm, Martin Sill, Andrey Korshunov, Tanja Eichkorn, Juliane Hörner-Rieber, Klaus Herfarth, Christine Jungk, Andreas Unterberg, Stefan Pfister, Wolfgang Wick, Andreas von Deimling, David Jones, Jürgen Debus, Felix Sahm, Laila König","doi":"10.1093/nop/npad004","DOIUrl":"10.1093/nop/npad004","url":null,"abstract":"<p><strong>Background: </strong>Molecular brain tumor classification using DNA methylation profiling has revealed that the methylation-class of pleomorphic xanthoastrocytoma (mcPXA) comprised a substantial portion of divergent initial diagnoses, which had been established based on histology alone. This study aimed to characterize the survival outcome in patients with mcPXAs-in light of the diverse selected treatment regimes.</p><p><strong>Methods: </strong>A retrospective cohort of adult mcPXAs were analyzed in regard to their progression-free survival following surgical resection and postoperative radiotherapy. Radiotherapy treatment plans were correlated with follow-up images to characterize the pattern of relapse. Treatment toxicities and molecular tumor characteristics were further analyzed.</p><p><strong>Results: </strong>Divergent initial histological diagnoses were encountered in 40.7%. There was no significant difference in local progression-free (PFS) and overall survival (OS) following gross total or subtotal resection. Postoperative radiotherapy was completed in 81% (22/27) following surgical intervention. Local PFS was 54.4% (95% CI: 35.3-84.0%) and OS was 81.3% (95% CI: 63.8-100%) after 3 years following postoperative radiotherapy. Initial relapses post-radiotherapy were primarily located in the previous tumor location and/or the planning target volume (PTV) (12/13). All patients in our cohort demonstrated the prognostically favorable <i>pTERT</i>-wildtype mcPXA.</p><p><strong>Conclusion: </strong>Our study demonstrated that adult patients with mcPXAs display a worse progression-free survival compared to the reported WHO grade 2 PXAs. Future matched-pair analyses are required with a non-irradiated cohort to elucidate the benefit of postoperative radiotherapy in adult patients with mcPXAs.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"307-314"},"PeriodicalIF":2.7,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9530410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling bias in survival of patients with incidentally discovered low-grade gliomas. 揭示偶然发现的低级别胶质瘤患者的生存偏差。
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2023-01-14 eCollection Date: 2023-04-01 DOI: 10.1093/nop/npad002
Derek R Johnson
{"title":"Unraveling bias in survival of patients with incidentally discovered low-grade gliomas.","authors":"Derek R Johnson","doi":"10.1093/nop/npad002","DOIUrl":"10.1093/nop/npad002","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"109-110"},"PeriodicalIF":2.7,"publicationDate":"2023-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9246418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forthcoming Meetings 即将到来的会议
Q2 CLINICAL NEUROLOGY Pub Date : 2023-01-13 DOI: 10.1093/nop/npac096
Journal Article Forthcoming Meetings Get access Neuro-Oncology Practice, Volume 10, Issue 1, February 2023, Page 108, https://doi.org/10.1093/nop/npac096 Published: 13 January 2023 Article history Corrected and typeset: 13 January 2023 Published: 13 January 2023
期刊文章即将召开的会议获取神经肿瘤学实践,第10卷,第1期,2023年2月,108页,https://doi.org/10.1093/nop/npac096出版:2023年1月13日文章历史更正和排版:2023年1月13日出版:2023年1月13日
{"title":"Forthcoming Meetings","authors":"","doi":"10.1093/nop/npac096","DOIUrl":"https://doi.org/10.1093/nop/npac096","url":null,"abstract":"Journal Article Forthcoming Meetings Get access Neuro-Oncology Practice, Volume 10, Issue 1, February 2023, Page 108, https://doi.org/10.1093/nop/npac096 Published: 13 January 2023 Article history Corrected and typeset: 13 January 2023 Published: 13 January 2023","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135898516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iatrogenic immunodeficiency-associated lymphoproliferative disorders of the central nervous system: a treatment paradox. 先天性免疫缺陷相关的中枢神经系统淋巴组织增生性疾病:治疗悖论。
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2022-12-31 eCollection Date: 2023-04-01 DOI: 10.1093/nop/npac098
Ramya Tadipatri, Chukwuyem Ekhator, Ram Narayan, Amir Azadi, Kevin C J Yuen, Jai Grewal, Ekokobe Fonkem

Background: Primary central nervous system lymphomas (PCNSLs) have historically had dismal survival rates until the advent of high-dose methotrexate (HD-MTX) based chemotherapy regimens. With increasing prevalence of autoimmune disease and development of new immunosuppressants, a genetically distinct entity known as iatrogenic immunodeficiency-associated lymphoproliferative disorder (LPD) has emerged. Many of these cases arise following methotrexate use, challenging feasibility of standard HD-MTX regimens. The aim of this study was to further characterize this disorder and determine the optimal management strategy.

Methods: We describe a case of a 76-year-old female with iatrogenic immunodeficiency-associated PCNSL successfully treated with surgical resection followed by an antiviral and rituximab based regimen. We then performed a systematic literature review and identified 58 cases of non-transplant iatrogenic immunodeficiency-associated LPD involving the CNS. We used a linear probability statistical model to determine correlations with outcome.

Results: Natalizumab was associated with EBV negative tumors (P = .023), and EBV positive tumors were associated with improved outcomes (P = .016). Surgical resection was associated with improved outcomes (P = .032), although limited by potential confounding effect. Antiviral treatment (P = .095), rituximab (P = .111), and stem cell transplant (SCT) (P = .198) showed a trend toward improved outcomes. The remaining treatments including methotrexate showed no improvement.

Conclusion: We propose that surgical resection, rituximab, and antiviral treatment may be considered as an alternative to standard HD-MTX based regimens when managing iatrogenic immunodeficiency-associated LPD of the CNS. Further study through prospective cohort studies or randomized clinical trials is warranted.

背景:在以大剂量甲氨蝶呤(HD-MTX)为基础的化疗方案出现之前,原发性中枢神经系统淋巴瘤(PCNSL)的生存率一直很低。随着自身免疫性疾病发病率的上升和新型免疫抑制剂的开发,出现了一种遗传学上不同的实体,即先天性免疫缺陷相关淋巴组织增生性疾病(LPD)。其中许多病例是在使用甲氨蝶呤后出现的,这对标准 HD-MTX 方案的可行性提出了挑战。本研究旨在进一步描述这种疾病的特征,并确定最佳治疗策略:我们描述了一例 76 岁女性先天性免疫缺陷相关 PCNSL 患者的病例,该患者在手术切除后接受了抗病毒和利妥昔单抗治疗,并取得了成功。随后,我们进行了系统性文献回顾,确定了 58 例累及中枢神经系统的非移植性先天性免疫缺陷相关 LPD 病例。我们使用线性概率统计模型来确定与结果的相关性:结果:纳他珠单抗与EBV阴性肿瘤相关(P = .023),EBV阳性肿瘤与预后改善相关(P = .016)。手术切除与预后改善相关(P = .032),但受到潜在混杂效应的限制。抗病毒治疗(P = .095)、利妥昔单抗(P = .111)和干细胞移植(SCT)(P = .198)显示出改善预后的趋势。结论:我们建议,在治疗先天性免疫缺陷相关的中枢神经系统LPD时,可考虑将手术切除、利妥昔单抗和抗病毒治疗作为基于HD-MTX的标准方案的替代方案。有必要通过前瞻性队列研究或随机临床试验进行进一步研究。
{"title":"Iatrogenic immunodeficiency-associated lymphoproliferative disorders of the central nervous system: a treatment paradox.","authors":"Ramya Tadipatri, Chukwuyem Ekhator, Ram Narayan, Amir Azadi, Kevin C J Yuen, Jai Grewal, Ekokobe Fonkem","doi":"10.1093/nop/npac098","DOIUrl":"10.1093/nop/npac098","url":null,"abstract":"<p><strong>Background: </strong>Primary central nervous system lymphomas (PCNSLs) have historically had dismal survival rates until the advent of high-dose methotrexate (HD-MTX) based chemotherapy regimens. With increasing prevalence of autoimmune disease and development of new immunosuppressants, a genetically distinct entity known as iatrogenic immunodeficiency-associated lymphoproliferative disorder (LPD) has emerged. Many of these cases arise following methotrexate use, challenging feasibility of standard HD-MTX regimens. The aim of this study was to further characterize this disorder and determine the optimal management strategy.</p><p><strong>Methods: </strong>We describe a case of a 76-year-old female with iatrogenic immunodeficiency-associated PCNSL successfully treated with surgical resection followed by an antiviral and rituximab based regimen. We then performed a systematic literature review and identified 58 cases of non-transplant iatrogenic immunodeficiency-associated LPD involving the CNS. We used a linear probability statistical model to determine correlations with outcome.</p><p><strong>Results: </strong>Natalizumab was associated with EBV negative tumors (<i>P</i> = .023), and EBV positive tumors were associated with improved outcomes (<i>P</i> = .016). Surgical resection was associated with improved outcomes (<i>P</i> = .032), although limited by potential confounding effect. Antiviral treatment (<i>P</i> = .095), rituximab (<i>P</i> = .111), and stem cell transplant (SCT) (<i>P</i> = .198) showed a trend toward improved outcomes. The remaining treatments including methotrexate showed no improvement.</p><p><strong>Conclusion: </strong>We propose that surgical resection, rituximab, and antiviral treatment may be considered as an alternative to standard HD-MTX based regimens when managing iatrogenic immunodeficiency-associated LPD of the CNS. Further study through prospective cohort studies or randomized clinical trials is warranted.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"169-175"},"PeriodicalIF":2.7,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9546597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five-year survivors from brain metastases treated with stereotactic radiosurgery: Biology, improving treatments, or just plain luck? 立体定向放射外科治疗脑转移瘤的五年幸存者:生物学、不断改进的治疗方法,还是纯粹的运气?
IF 2.7 Q2 CLINICAL NEUROLOGY Pub Date : 2022-12-13 eCollection Date: 2023-04-01 DOI: 10.1093/nop/npac095
Jane B Pearce, Fang-Chi Hsu, Claire M Lanier, Christina K Cramer, Jimmy Ruiz, Hui-Wen Lo, Fei Xing, Margaret Smith, Wencheng Li, Christopher Whitlow, Jaclyn J White, Stephen B Tatter, Adrian W Laxton, Michael D Chan

Background: Improvements in therapies have led to an increasing number of long-term survivors of brain metastases. The present series compares a population of 5-year survivors of brain metastases to a generalized brain metastases population to assess for factors attributable to long-term survival.

Methods: A single institution retrospective review was performed to identify 5-year survivors of brain metastases who received stereotactic radiosurgery (SRS). A historical control population of 737 patients with brain metastases was used to assess similarities and differences between the long-term survivor population and the general population treated with SRS.

Results: A total of 98 patients with brain metastases were found to have survived over 60 months. No differences between long-term survivors and controls were identified with regards to the age at first SRS (P = .19), primary cancer distribution (P = .80), and the number of metastases at first SRS (P = .90). Cumulative incidence of neurologic death at 6, 8 and 10 years for the long-term survivor cohort was 4.8%, 16%, and 16% respectively. In the historical controls, cumulative incidence of neurologic death reached a plateau at 40% after 4.9 years. A significant difference in the distribution of burden of disease at the time of the first SRS was found between the 5-year survivors and the control (P = .0049). 58% of 5-year survivors showed no evidence of clinical disease at the last follow-up.

Conclusion: Five-year survivors of brain metastases represent a diverse histologic population, suggesting a small population of oligometastatic and indolent cancers exist for each cancer type.

背景:随着治疗方法的改进,脑转移瘤长期存活者的人数不断增加。本研究比较了脑转移瘤 5 年存活者和全身性脑转移瘤存活者,以评估影响长期存活的因素:方法:对单个机构进行了回顾性审查,以确定接受立体定向放射外科手术(SRS)的脑转移瘤 5 年存活者。结果:共有98名脑转移瘤患者接受了立体定向放射外科手术(SRS)治疗:结果:共发现98名脑转移患者存活超过60个月。在首次接受 SRS 时的年龄(P = .19)、原发癌分布(P = .80)和首次接受 SRS 时的转移灶数量(P = .90)方面,长期幸存者与对照组之间没有发现差异。长期幸存者队列中,6年、8年和10年的神经系统死亡累积发生率分别为4.8%、16%和16%。在历史对照组中,神经系统死亡的累积发生率在 4.9 年后达到 40%的高点。首次接受 SRS 时的疾病负担分布在 5 年期幸存者和对照组之间存在明显差异(P = .0049)。58%的5年生存者在最后一次随访时没有临床疾病的迹象:结论:脑转移瘤五年生存者代表了一个多样化的组织学群体,这表明每种癌症类型都有一小部分寡转移和不活跃癌症患者。
{"title":"Five-year survivors from brain metastases treated with stereotactic radiosurgery: Biology, improving treatments, or just plain luck?","authors":"Jane B Pearce, Fang-Chi Hsu, Claire M Lanier, Christina K Cramer, Jimmy Ruiz, Hui-Wen Lo, Fei Xing, Margaret Smith, Wencheng Li, Christopher Whitlow, Jaclyn J White, Stephen B Tatter, Adrian W Laxton, Michael D Chan","doi":"10.1093/nop/npac095","DOIUrl":"10.1093/nop/npac095","url":null,"abstract":"<p><strong>Background: </strong>Improvements in therapies have led to an increasing number of long-term survivors of brain metastases. The present series compares a population of 5-year survivors of brain metastases to a generalized brain metastases population to assess for factors attributable to long-term survival.</p><p><strong>Methods: </strong>A single institution retrospective review was performed to identify 5-year survivors of brain metastases who received stereotactic radiosurgery (SRS). A historical control population of 737 patients with brain metastases was used to assess similarities and differences between the long-term survivor population and the general population treated with SRS.</p><p><strong>Results: </strong>A total of 98 patients with brain metastases were found to have survived over 60 months. No differences between long-term survivors and controls were identified with regards to the age at first SRS (<i>P</i> = .19), primary cancer distribution (<i>P</i> = .80), and the number of metastases at first SRS (<i>P</i> = .90). Cumulative incidence of neurologic death at 6, 8 and 10 years for the long-term survivor cohort was 4.8%, 16%, and 16% respectively. In the historical controls, cumulative incidence of neurologic death reached a plateau at 40% after 4.9 years. A significant difference in the distribution of burden of disease at the time of the first SRS was found between the 5-year survivors and the control (<i>P</i> = .0049). 58% of 5-year survivors showed no evidence of clinical disease at the last follow-up.</p><p><strong>Conclusion: </strong>Five-year survivors of brain metastases represent a diverse histologic population, suggesting a small population of oligometastatic and indolent cancers exist for each cancer type.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"195-202"},"PeriodicalIF":2.7,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9246417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neuro-oncology practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1